Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis
Clinical Immunology · 2023
DOI: 10.1016/j.clim.2023.109294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2023. Verfasst von Liu Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medici…. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Psoriasis is a chronic inflammatory skin disease mediated by immune and complex genetic factors. The wingless-related integration site (Wnt) signaling pathway plays a critical role in psoriasis, but how the Wnt pathway is regulated in psoriatic skin and whether it can be exploited for therapeutic benefits is unclear. By comparing biopsies from healthy and psoriatic skin, we found that Wnt inhibitory factor 1 (WIF1), an inhibitor of Wnt signaling, showed reduced expression at both mRNA and protein levels in psoriatic skin. We then quantified methylation of the WIF1 gene promoter by DNA methylation sequencing and found that the WIF1 promoter region was hypermethylated. We further showed that recombinant WIF1 injection ameliorates the imiquimod (IMQ) mouse model of psoriasis. We also revealed that treatment with the DNA methylation inhibitor, decitabine, inhibited proliferation of immortalized human keratinocytes (HaCaT) in a psoriasis-like inflammatory environment. Finally, we applied decitabine to the IMQ mouse model and demonstrated that treatment of mice with decitabine ameliorates the disease. Therefore, our study reveals that methylation of the WIF1 gene is associated with the pathogenesis of psoriasis, and suggests that pharmacological targeting of DNA methylation is a potential treatment strategy for psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China; Institute of Dermatology, Shanghai Academy…
- Institute for Cancer Research, Shenzhen Bay Laboratory, Shenzhen 518107, China.
- Institute for Cancer Research, Shenzhen Bay Laboratory, Shenzhen 518107, China. Electronic address: yincq@szbl.ac.cn.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Liu, L., Zhou, Y., Luo, D., Sun, X., Li, H., Lu, Y., Wang, J., Zhang, M., Lin, N., Yin, C., & Li, X. (2023). Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis. Clinical Immunology. https://doi.org/10.1016/j.clim.2023.109294
Vancouver
Liu L, Zhou Y, Luo D, Sun X, Li H, Lu Y, et al. Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis. Clinical Immunology. 2023. doi:10.1016/j.clim.2023.109294
BibTeX
@article{Liu2023,
author = {Liu, Liu and Zhou, Yaqiong and Luo, Dan and Sun, Xiaoying and Li, Hongjin and Lu, Yi and Wang, Jiao and Zhang, Miao and Lin, Naixuan and Yin, Chengqian and Li, Xin},
title = {Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis},
journal = {Clinical Immunology},
year = {2023},
doi = {10.1016/j.clim.2023.109294}
}
EUVIMED